PRKAR1A-related acrodysostosis with partial growth hormone deficiency: 18-month response to recombinant human growth hormone.

Authors

Sokratis Katsoudas, Angeliki Kokkinou, Afroditi Nikolopoulou, Evangelia Tsitsekli, Ioulia Polychroni, Paraskevi Zosi

Published in

Hormones (Athens, Greece). Jul 14, 2026. Epub Jul 14, 2026.

Abstract

To describe the 18-month auxological response to recombinant human growth hormone (rhGH) therapy in a pediatric patient with genetically confirmed PRKAR1A-related acrodysostosis and partial growth hormone deficiency (GHD).
A 3-year-9-month-old boy with genetically confirmed PRKAR1A-related acrodysostosis underwent comprehensive endocrine evaluation due to progressive growth deceleration. Growth hormone (GH) secretion was assessed using two pharmacological stimulation tests (glucagon and L-dopa). rhGH therapy was initiated and titrated based on clinical and biochemical response, with serial auxological and biochemical follow-up over 18 months.
At presentation (3 years 9 months), height was - 2.92 SDS with a growth velocity of 3 cm/year over the preceding year. Two stimulation tests demonstrated peak GH levels of 8 ng/mL and 5.5 ng/mL, consistent with partial GHD. Brain MRI revealed mild anterior pituitary hypoplasia. After 18 months of rhGH therapy, height increased from 89 cm to 103.5 cm and height SDS improved from - 2.92 to - 1.52 (Δ + 1.40 SDS), with a first-year height velocity of 11 cm/year. Bone age advanced from 2 years 8 months at treatment initiation to 4 years 6 months at 18 months. Serum IGF-1 increased while remaining within the age-adjusted laboratory reference range, and no adverse effects were observed during follow-up.
To our knowledge, this represents the second published pediatric case of type 1 acrodysostosis with documented partial GHD treated with rhGH. The marked auxological response over 18 months supports the concept that central GH axis impairment may coexist with the intrinsic skeletal pathology of the disorder in some patients.

PMID:
42449097
Bibliographic data and abstract were imported from PubMed on 15 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.